22 July 2020
Visiongain has launched a new report Medical Imaging Market Report 2020-2030: Forecast by Imaging Technology (X-ray, Tomography (Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Single-Photon Emission Tomography), Ultrasound Imaging (2D Ultrasound Systems, 3D and 4D Ultrasound Systems, Doppler Imaging), Radiographic Imaging, Other Imaging Technologies)), by Type (2D Imaging, 3D/4D Imaging), by Software Type (Standalone Software, Integrated Software), by Application (Cardiology, Dental, Mammography, Neurology, Oncology, Orthopaedic, Obstetrics & Gynaecology, Urology and Nephrology), by End Users (Ambulatory Surgical Centers, Clinics, Diagnostic Centers, Hospitals, and Research & Academic Institutions) and by Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). Including Forecasts by Major Developed Countries and Developing Countries, Plus Profiles of Leading Companies.
Medical imaging are non-invasive techniques that allow doctors to diagnose diseases and injuries without being intrusive. It has become an essential module of the entire health-care continuum, from screening, early diagnosis, and follow-up. Medical imaging procedures are also used by doctors to determine the best treatment options for patients. Medical imaging tests helps doctors to obtain a better view of organs, blood vessels, tissues, bones, locate tumours, blood clots and other blockages. It also guide medical procedures involving placement of catheters, stents, or other devices inside the body.
According to the Medicare Payment Advisory Commission (MedPAC) and the Centers for Medicare and Medicaid Services (CMS), the rise in volume of imaging services per Medicare beneficiary exceeded the growth of all other services physicians provide. The success of medical imaging is not only about technological advances but also the digital revolution which helped to replace films, permitting multi-planar image reconstruction. Advancements in image acquisition, analysis, transfer, and storage have put medical imaging at the forefront of medical diagnosis. Thus, advances in medical imaging will transform medicine for the masses into precision medicine with personalized care.
The Visiongain report analyst commented “Factors such as increasing demand for early-stage diagnosis of chronic disease and rising aging demographics are anticipated to boost the growth of medical imaging market. In addition, increasing investments, funds, and grants by public-private organizations further drives the market growth.”
On the other hand, shortage of helium, high cost of imaging modalities and unfavourable reimbursement scenario in emerging countries may limit market growth.
The report covers a detailed competitive outlook that includes market share and company profiles of key players operating in the global market. Key players profiled in the report include GE Healthcare, Philips Healthcare, Hitachi Medical Corporation, Hologic, Inc., Siemens Healthcare, Samsung Medison, Shimadzu Corporation, Toshiba Medical Systems Corporation, Esaote S.P.A, and Fujifilm Corporation.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.